TrialEsophagus : official journal of the Japan Esophageal Society2026

First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.

Ken Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.